Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
FULC — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

8.7

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

EPS Last/This Y

-0.12

EPS This/Next Y

-0.3

Price

7.83

Target Price

19

Analyst Recom

1.5

Performance Q

-27.77

Upside

-295.9%

Beta

3.37

Ticker: FULC



16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09FULC7.930.491.559673
2026-03-10FULC80.512.279694
2026-03-11FULC7.770.51999.999714
2026-03-12FULC7.630.501.689657
2026-03-13FULC7.630.501.689657
2026-03-17FULC7.410.51999.999895
2026-03-18FULC6.90.550.1710195
2026-03-20FULC6.810.410.9411750
2026-03-25FULC6.970.210.5910975
2026-03-26FULC6.930.210.1710960
2026-03-27FULC6.720.210.0010965
2026-03-30FULC6.560.200.0011529
2026-03-31FULC7.670.190.0612126
2026-04-01FULC7.470.180.0012331
2026-04-06FULC7.820.181.3812618
2026-04-07FULC7.830.170.0012577
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09FULC7.93-7.4- -1.30
2026-03-10FULC8.00-7.4- -1.30
2026-03-11FULC7.77-7.4- -1.30
2026-03-12FULC7.62-7.4- -1.30
2026-03-13FULC7.65-7.4- -1.30
2026-03-17FULC7.41-7.4- -1.30
2026-03-18FULC6.91-7.4- -1.30
2026-03-19FULC7.03-7.4- -1.30
2026-03-20FULC6.81-7.4- -1.30
2026-03-23FULC6.88-7.4- -1.30
2026-03-24FULC6.70-7.4- -1.30
2026-03-25FULC6.97-7.4- -1.30
2026-03-26FULC6.93-7.4- -1.30
2026-03-27FULC6.71-7.4- -1.30
2026-03-30FULC6.57-7.4- -1.30
2026-03-31FULC7.68-7.4- -1.30
2026-04-01FULC7.47-7.4- -1.30
2026-04-02FULC8.03-7.4- -1.30
2026-04-06FULC7.82-7.4- -1.30
2026-04-07FULC7.83-7.4- -1.30
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09FULC-29.9327.536.20
2026-03-10FULC-29.9327.536.20
2026-03-11FULC-29.9327.537.43
2026-03-12FULC-29.9327.537.43
2026-03-13FULC-29.9327.537.43
2026-03-18FULC-29.9327.507.43
2026-03-19FULC-29.9327.507.43
2026-03-20FULC-29.9327.507.43
2026-03-23FULC-29.9327.507.43
2026-03-24FULC-29.9327.507.43
2026-03-25FULC-29.9327.508.70
2026-03-26FULC-29.9327.508.70
2026-03-27FULC-29.9327.508.70
2026-03-30FULC-29.9327.538.70
2026-03-31FULC-29.9327.538.70
2026-04-01FULC-29.9327.538.70
2026-04-02FULC-29.9327.538.70
2026-04-06FULC-29.9327.528.70
2026-04-07FULC-29.9327.528.70
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

-0.31

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

-0.31

Insider Transactions

-29.93

Institutional Transactions

27.52

Beta

3.37

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

10

Growth Score

18

Sentiment Score

67

Actual DrawDown %

76.3

Max Drawdown 5-Year %

-92.7

Target Price

19

P/E

Forward P/E

PEG

P/S

P/B

1.49

P/Free Cash Flow

EPS

-1.18

Average EPS Est. Cur. Y​

-1.3

EPS Next Y. (Est.)

-1.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.87

Return on Equity vs Sector %

-48.9

Return on Equity vs Industry %

-32.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.08

EBIT Estimation

◆ FULC Healthcare
$7.83
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
14/20
Pullback
15/25
Volume
7/15
Valuation
12/20
TP/AR
4/10
Options
7/10
RSI
50.2
Range 1M
72.1%
Sup Dist
2%
🚀
Momentum Growth
Ride accelerating trends
N/A
27 /100
WEAK
Momentum
5/25
Growth
4/30
Estimates
4/20
Inst/Vol
6/15
Options
8/10
EPS Yr
-7.9%
EPS NY
-22.9%
52W%
40%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +142.7% upside
Quality
2/30
Valuation
16/30
Growth
1/25
Stability
9/10
LT Trend
3/5
Upside
+142.7%
Quality
10
Click a card to see score breakdown Full Analysis →
Fulcrum Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 55
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC

Latest News

—
Caricamento notizie per FULC…
stock quote shares FULC – Fulcrum Therapeutics Inc Stock Price stock today
news today FULC – Fulcrum Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FULC – Fulcrum Therapeutics Inc yahoo finance google finance
stock history FULC – Fulcrum Therapeutics Inc invest stock market
stock prices FULC premarket after hours
ticker FULC fair value insiders trading